Kymera Therapeutics stock reports 465.2 percent revenue growth
AD HOC NEWS
Kymera Therapeutics reported a significant 465.2% year-over-year revenue growth in Q2 2026, reaching USD 65.0 million, primarily driven by collaboration income. The company also beat analyst estimates for adjusted loss per share. Stifel Nicolaus raised its price target for Kymera to USD 152.00, maintaining a Buy rating, highlighting the company's platform in targeted protein degradation and oral medicines for inflammatory diseases.
Read the full story
This is a short summary. The complete article is published by AD HOC NEWS.
Headline and summary aggregated from public news feeds. For information only — not financial advice.